WORKING OUT OF STRATEGY OF STOREKEEPING OF PHARMACEUTICAL FIRM
Research of experience of the firm which is engaged in pharmaceutical business, has confirmed necessity of working out the scientifically-proved strategy of storekeeping by different groups of medicines. Instability of economy during the periods of crisis, instability of prices on pharmaceutical pro...
Saved in:
Main Author: | |
---|---|
Format: | Book |
Published: |
IRBIS LLC,
2015-03-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
MARC
LEADER | 00000 am a22000003u 4500 | ||
---|---|---|---|
001 | doaj_d62c085d0b7b4cd69b2f51e824f60b5d | ||
042 | |a dc | ||
100 | 1 | 0 | |a A. I. Borodin |e author |
245 | 0 | 0 | |a WORKING OUT OF STRATEGY OF STOREKEEPING OF PHARMACEUTICAL FIRM |
260 | |b IRBIS LLC, |c 2015-03-01T00:00:00Z. | ||
500 | |a 2070-4909 | ||
500 | |a 2070-4933 | ||
520 | |a Research of experience of the firm which is engaged in pharmaceutical business, has confirmed necessity of working out the scientifically-proved strategy of storekeeping by different groups of medicines. Instability of economy during the periods of crisis, instability of prices on pharmaceutical production and inflation generate risks, both for firm, and for its foreign partners. For the purpose of optimum strategy creation storekeeping of medicines is grouped by consumer properties, for each group demand is investigated and depending on features of demand optimum strategy of storekeeping with use of dynamic models, periodic and with critical level is developed. Efficiency is received at the expense of economy of operating assets, improvements of servicing and increase of attractiveness of pharmaceutical business for domestic and foreign partners-suppliers of production. | ||
546 | |a RU | ||
690 | |a medical products | ||
690 | |a working capital | ||
690 | |a stock norm | ||
690 | |a management strategy | ||
690 | |a demand modeling | ||
690 | |a seasonal prevalence of sale | ||
690 | |a network of stocks movement | ||
690 | |a critical rate strategic | ||
690 | |a threshold level of stock | ||
690 | |a order volume | ||
690 | |a storage costs | ||
690 | |a organization costs | ||
690 | |a Therapeutics. Pharmacology | ||
690 | |a RM1-950 | ||
690 | |a Economics as a science | ||
690 | |a HB71-74 | ||
655 | 7 | |a article |2 local | |
786 | 0 | |n Фармакоэкономика, Vol 5, Iss 2, Pp 34-36 (2015) | |
787 | 0 | |n https://www.pharmacoeconomics.ru/jour/article/view/32 | |
787 | 0 | |n https://doaj.org/toc/2070-4909 | |
787 | 0 | |n https://doaj.org/toc/2070-4933 | |
856 | 4 | 1 | |u https://doaj.org/article/d62c085d0b7b4cd69b2f51e824f60b5d |z Connect to this object online. |